Abstract
Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs designed as targeted therapies for the treatment of cancer. Among the challenges in generating an effective ADC is the choice of an effective conjugation site on the IgG. One common method to prepare site-specific ADCs is to engineer solvent-accessible cysteine residues into antibodies. Here, we used X-ray diffraction and hydrogen-deuterium exchange mass spectroscopy to analyze the structure and dynamics of such a construct where a cysteine has been inserted after Ser 239 (Fc-239i) in the antibody heavy chain sequence. The crystal structure of this Fc-C239i variant at 0.23 nm resolution shows that the inserted cysteine structurally replaces Ser 239 and that this causes a domino-like backward shift of the local polypeptide, pushing Pro 238 out into the hinge. Proline is unable to substitute conformationally for the wild-type glycine at this position, providing a structural reason for the previously observed abolition of both FcγR binding and antibody-dependent cellular cytotoxicity. Energy estimates for the both the FcγR interface (7 kcal/mol) and for the differential conformation of proline (20 kcal/mol) are consistent with the observed disruption of FcγR binding, providing a quantifiable case where strain at a single residue appears to disrupt a key biological function. Conversely, the structure of Fc-C239i is relatively unchanged at the intersection of the CH2 and CH3 domains; the site known to be involved in binding of the neonatal Fc receptor (FcRn), and an alignment of the Fc-C239i structure with an Fc structure in a ternary Fc:FcRn:HSA (human serum albumin) complex implies that these favorable contacts would be maintained. Hydrogen deuterium exchange mass spectroscopy (HDX-MS) data further suggest a significant increase in conformational mobility for the Fc-C239i protein relative to Fc that is evident even far from the insertion site but still largely confined to the CH2 domain. Together, the findings provide a detailed structural and dynamic basis for previously observed changes in ADC functional binding to FcγR, which may guide further development of ADC designs.
Highlights
Monoclonal antibodies have become central to anticancer strategies, including their use in delivering cytotoxins to epitopically-targeted malignant cells
The insertions before and after S239 (i.e., C238i and C239i) showed a new feature: abolition of antibody-dependent cellular cytotoxicity (ADCC) due to non-binding of Fc gamma receptor IIIA (FcγRIIIA). This could be advantageous for antibody-drug conjugates (ADCs) therapies, since binding to FcγRIIIA can lead to internalization of the toxin by nontarget cells and consequent side effects
The average back-exchange was observed to be 24% using a highly deuterated 9-peptide standard. This level of back-exchange is similar to previous reports [14,15,16]. For both the Hydrogen-deuterium exchange (HDX) and diffraction-based dynamics comparisons, wild-type measurements for each amino acid were subtracted from the corresponding measurements for Fc-C239i
Summary
Monoclonal antibodies have become central to anticancer strategies, including their use in delivering cytotoxins to epitopically-targeted malignant cells Simple in concept, these antibody-drug conjugates (ADCs) are large multi-component constructs requiring an approach that must address several overlapping challenges, including epitope selection, linker design, and control over conjugation. These antibody-drug conjugates (ADCs) are large multi-component constructs requiring an approach that must address several overlapping challenges, including epitope selection, linker design, and control over conjugation Each of these issues has seen key innovation in the past decade, enabling a recent expansion to over 50 therapeutic candidates currently in clinical trials [1], and five ADC’s approved for clinical use (Mylotar, Adcetris, Kadcyla, Bespona, and Polivy). Implications for molecular energetics and for conjugate design strategies are discussed
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have